Market closedNon-fractional
Catalyst Pharmaceuticals/CPRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Ticker
CPRX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Coral Gables, United States
Employees
167
Website
www.catalystpharma.com
CPRX Metrics
BasicAdvanced
$2.1B
Market cap
30.80
P/E ratio
$0.56
EPS
0.70
Beta
-
Dividend rate
Price and volume
Market cap
$2.1B
Beta
0.7
Financial strength
Current ratio
5.085
Quick ratio
4.663
Long term debt to equity
0.551
Total debt to equity
0.551
Management effectiveness
Return on assets (TTM)
9.29%
Return on equity (TTM)
14.55%
Valuation
Price to earnings (TTM)
30.803
Price to revenue (TTM)
4.607
Price to book
3.66
Price to tangible book (TTM)
5.45
Price to free cash flow (TTM)
41.568
Growth
Revenue change (TTM)
60.38%
Earnings per share change (TTM)
-36.55%
3-year revenue growth (CAGR)
50.72%
3-year earnings per share growth (CAGR)
-6.04%
What the Analysts think about CPRX
Analyst Ratings
Majority rating from 7 analysts.
CPRX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$99M
-10.86%
Net income
$23M
-33.33%
Profit margin
23.55%
-25.21%
CPRX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.33
-$0.29
$0.31
$0.19
-
Expected
$0.36
-$0.29
$0.27
$0.17
$0.26
Surprise
-7.30%
1.75%
16.98%
14.46%
-
CPRX News
AllArticlesVideos
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
GlobeNewsWire·3 days ago
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
GlobeNewsWire·5 days ago
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Catalyst Pharmaceuticals stock?
Catalyst Pharmaceuticals (CPRX) has a market cap of $2.1B as of July 27, 2024.
What is the P/E ratio for Catalyst Pharmaceuticals stock?
The price to earnings (P/E) ratio for Catalyst Pharmaceuticals (CPRX) stock is 30.8 as of July 27, 2024.
Does Catalyst Pharmaceuticals stock pay dividends?
No, Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Catalyst Pharmaceuticals dividend payment date?
Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals (CPRX) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Catalyst Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.